CapsoVision (NASDAQ:CV) Stock Price Crosses Above 200 Day Moving Average – Here’s Why

Posted by George Bondi on Nov 11th, 2026

CapsoVision, Inc. (NASDAQ:CV – Get Free Report) shares passed above its 200-day moving average during trading on Monday. The stock has a 200-day moving average of $6.35 and traded as high as $6.56. CapsoVision shares last traded at $6.44, with a volume of 66,462 shares changing hands.

Analyst Ratings Changes

CV has been the topic of several research reports. Benchmark reiterated a “speculative buy” rating on shares of CapsoVision in a report on Friday, August 14th. Weiss Ratings restated a “sell (d-)” rating on shares of CapsoVision in a research note on Friday, September 25th. Zacks Research raised CapsoVision to a “hold” rating in a research report on Monday, August 31st. Finally, Roth Capital started coverage on CapsoVision in a research note on Friday, August 28th. They set a “buy” rating and a $9.00 price target on the stock. Two investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $9.50.

Check Out Our Latest Analysis on CapsoVision

CapsoVision Stock Performance

The firm has a 50 day simple moving average of $6.52 and a two-hundred day simple moving average of $6.35.

CapsoVision (NASDAQ:CV – Get Free Report) last posted its earnings results on Thursday, August 13th. The company reported ($0.15) earnings per share (EPS) for the quarter. The firm had revenue of $3.64 million during the quarter. CapsoVision had a negative return on equity of 177.85% and a negative net margin of 214.74%. On average, equities research analysts anticipate that CapsoVision, Inc. will post -0.56 earnings per share for the current year.

Insider Activity

In other news, major shareholder Ching Hang Shen acquired 878,734 shares of the firm’s stock in a transaction on Tuesday, September 15th. The stock was purchased at an average price of $5.69 per share, for a total transaction of $4,999,996.46. Following the purchase, the insider owned 2,926,655 shares in the company, valued at approximately $16,652,666.95. This represents a 42.91% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, major shareholder Eliyahou Et Al Harari acquired 1,757,469 shares of the firm’s stock in a transaction on Friday, September 18th. The stock was purchased at an average price of $5.69 per share, with a total value of $9,999,998.61. Following the purchase, the insider owned 1,396,494 shares in the company, valued at approximately $7,946,050.86. The trade was a -486.87% increase in their position. The SEC filing for this purchase provides additional information. 2.30% of the stock is currently owned by insiders.

Institutional Trading of CapsoVision

Institutional investors and hedge funds have recently modified their holdings of the business. BlackRock Inc. purchased a new position in CapsoVision in the second quarter worth $14,372,000. Bank of New York Mellon Corp purchased a new stake in shares of CapsoVision during the 2nd quarter valued at $569,000. Deutsche Bank AG purchased a new stake in shares of CapsoVision during the 2nd quarter valued at $263,000. Bank of America Corp DE purchased a new stake in shares of CapsoVision during the 2nd quarter valued at $193,000. Finally, Connective Capital Management LLC bought a new stake in shares of CapsoVision during the 2nd quarter worth $76,000.

About CapsoVision

(Get Free Report)

CapsoVision, Inc. is a medical technology company focused on developing and commercializing diagnostic solutions for gastrointestinal diseases. The company’s primary product is the CapsoCam Plus capsule endoscope, an ingestible camera that captures images of the gastrointestinal tract as it passes through the digestive system. CapsoCam Plus is designed to provide panoramic imaging, including a 360-degree view, to help physicians examine areas of the small bowel that can be difficult to assess using conventional endoscopy.